New CSL venture ready for take off

CSL has finally completed its mammoth Vifor acquisition, after two delays due to regulatory speed bumps.

In December last year CSL announced the AU$17.2 billion buy of the Swiss pharma to get a solid position in the renal market. Expected to be closed by March, the settlement was postponed for four months until 22 July. Then on 13 July it was again postponed, to 30 September, waiting on regulatory clearances.

Today CSL released an ASX announcement stating that all clearances have been received, and the deal is expected to be finalised by 9 August 2022.